US equities |
MU $1,029.00 ▼-0.66% NVDA $229.28 ▼-0.52% SPCX $162.57 ▲+1.25% TSLA $382.70 ▲+2.05% AAPL $336.64 ▼-1.11% MSFT $535.07 ▲+2.38% AMZN $262.43 ▲+3.29% META $718.67 ▼-0.31%
FinancialContent

Articles published by ALTERITY THERAPEUTICS LIMITED

< Previous 1 2 3 Next >
News headline image
Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Tickers ASX ATHE
News headline image
Alterity Therapeutics to Present at the MST Access ‘Hidden Gems in Life Sciences’ Webinar
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Tickers ASX ATHE
News headline image
Alterity Therapeutics to Host Webcast Today on New Data from the bioMUSE Natural History Study
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Tickers ASX ATHE
News headline image
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Tickers ASX ATHE
News headline image
Appendix 4C – Q3 FY24 Quarterly Cash Flow Report
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Tickers ASX ATHE
News headline image
Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich’s Ataxia
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Tickers ASX ATHE
News headline image
Alterity Therapeutics Parkinson’s Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Tickers ASX ATHE
News headline image
Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Tickers ASX ATHE
News headline image
Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Tickers ASX ATHE
News headline image
Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Tickers ASX ATHE
News headline image
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Tickers ASX ATHE
News headline image
Alterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This Week
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Tickers ASX ATHE
News headline image
Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Tickers ASX ATHE
News headline image
Alterity Therapeutics Appoints Phillip Hains as Chief Financial Officer
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Tickers ASX ATHE
News headline image
Alterity Therapeutics to Host Webcast to Discuss ATH434 Efficacy Data in Primates and Recent Clinical Progress
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Tickers ASX ATHE
News headline image
Alterity Therapeutics Reports Positive Efficacy Data for ATH434 in a Primate Model of Parkinson’s Disease
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Tickers ASX ATHE
News headline image
Alterity Therapeutics Announces Presentation of Novel Biomarker Data for Evaluation of Multiple System Atrophy
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Tickers ASX ATHE
News headline image
Alterity Therapeutics Announces Presentation of New Data Demonstrating Novel Mechanisms of ATH434
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Tickers ASX ATHE
News headline image
Alterity Therapeutics Completes Enrolment in ATH434-201 Phase 2 Clinical Trial in Multiple System Atrophy
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Tickers ASX ATHE
News headline image
Appendix 4C – Q1 FY24 Quarterly Cash Flow Report
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Tickers ASX ATHE
News headline image
Alterity Therapeutics Presents New Data on Multiple System Atrophy, a Rare Parkinsonian Disorder
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Tickers ASX ATHE
News headline image
Alterity Therapeutics Granted New Composition of Matter Patent in Europe for Neurodegenerative Diseases including Parkinson’s and Alzheimer’s
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Tickers ASX ATHE
News headline image
Alterity Therapeutics Rare Disease Natural History Study to be Featured at the International Congress of Parkinson’s Disease and Movement Disorders
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Tickers ASX ATHE
News headline image
Alterity Therapeutics Receives a $4.74 million Research & Development Tax Incentive Refund
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Tickers ASX ATHE
News headline image
Appendix 4C – Q4 FY23 Quarterly Cash Flow Report
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Tickers ASX ATHE
News headline image
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Tickers ASX ATHE
News headline image
Alterity Therapeutics to Present in MST Access Rare Diseases, Rich Returns Forum on 22 June 2023
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Tickers ASX ATHE
News headline image
Alterity Therapeutics Initiates Second Phase 2 Study in Rare Parkinsonian Disorder
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Tickers ASX ATHE
News headline image
Alterity Therapeutics CEO David Stamler to Present at the SHARE Series Monday Management Update on Monday, May 22, 2023
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Tickers ASX ATHE
News headline image
Appendix 4C – Q3 FY23 Quarterly Cash Flow Report
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Tickers ASX ATHE
< Previous 1 2 3 Next >